Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 8.01, 9.01 · 8-K

Tonix Pharmaceuticals Holding Corp.

TNXPNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. On September 22, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced it entered into an agreement with a pharmacy benefit manager, effective immediately, that provides coverage for TONMYA® to approximately 21 million Medicare Part D plan beneficiaries. To date, government and commercial coverage of TONMYA is available to a total of approximately 166 million individuals.…

Filed Sep 22, 2026Accepted Sep 22, 2026, 7:05 AM EDTCIK 1430306Accession 0001493152-26-043644
Share

Company context

Current securities

Recent company filings

  1. Other EventsSep 8, 2026
  2. 4 filingAug 24, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsAug 18, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. 10-Q filingAug 10, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On September 22, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced it entered into an agreement with a pharmacy benefit manager, effective immediately, that provides coverage for TONMYA® to approximately 21 million Medicare Part D plan beneficiaries. To date, government and commercial coverage of TONMYA is available to a total of approximately 166 million individuals. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.